Method of Classifying a Sample Based on Determination of Fgfr

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a method for classifying samples from patients who have or are at risk of developing urothelial or bladder cancer by analyzing the status of genes known as FGFR1, FGFR2, FGFR3, or FGFR4. The method detects alterations or changes in expression of these genes, particularly through PCR-based, hybridization, or immunological assays. Based on the results, the method classifies patients into groups with good or poor prognosis for standard anti-cancer treatments and helps decide if alternative treatments, such as FGFR inhibitors, might be more effective.

Use CasesContent extracted from patent full text and abstract with AI.

• Personalized treatment planning for patients with bladder or urothelial cancer by determining their suitability for conventional anti-cancer agents or FGFR-targeted therapies.
• Early detection and risk stratification of urothelial or bladder cancer in individuals at risk, enabling preventative or more targeted therapeutic interventions.
• Development of diagnostic kits for hospitals and laboratories to rapidly identify genetic changes in FGFR genes in cancer tissue samples.
• Research applications in oncology to better understand the role of FGFR alterations in cancer progression and therapeutic response.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables precision medicine by matching patients with the most effective therapies based on molecular characteristics of their tumors.
• Improves prognosis for patients who may not respond well to traditional therapies by identifying candidates for FGFR inhibitor treatments.
• Facilitates faster and more accurate decision-making by clinicians through standardized and reliable diagnostic tests.
• Potentially leads to cost savings by avoiding ineffective treatments and focusing resources on therapies likely to be successful.
• Broad applicability to both advanced and early-stage urothelial or bladder cancers, and potentially to other FGFR-altered tumors.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a method of classifying a sample of a patient that suffers from or being at risk of developing urothelial or bladder cancer, said method comprising the steps of: a) determining in said sample from said patient, the presence or absence of alteration in an FGFR gene and/or the expression level of at least one gene encoding for a receptor selected from the group consisting of FGFR1, FGFR2, FGFR3 or FGFR4, and b) classifying the sample of said patient from the outcome of step a) into one of at least two classifications, said classifications comprising good and poor prognosis for treatment with an anti-cancer agent.